Mirjam Blattner1, Daniel J Lee2, Catherine O'Reilly1, Kyung Park1, Theresa Y MacDonald1, Francesca Khani1, Kevin R Turner1, Ya-Lin Chiu3, Peter J Wild4, Igor Dolgalev5, Adriana Heguy5, Andrea Sboner6, Sinan Ramazangolu7, Haley Hieronymus5, Charles Sawyers5, Ashutosh K Tewari8, Holger Moch4, Ghil Suk Yoon9, Yong Chul Known10, Ove Andrén11, Katja Fall12, Francecsa Demichelis13, Juan Miguel Mosquera1, Brian D Robinson2, Christopher E Barbieri2, Mark A Rubin14. 1. Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY. 2. Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY ; Department of Urology, Weill Medical College of Cornell University, New York, NY. 3. Department of Biostatistics and Epidemiology, Weill Medical College of Cornell University and New York-Presbyterian Hospital, New York, NY. 4. Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. 5. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY. 6. Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY ; Institute for Computational Biomedicine, Weill Medical College of Cornell University, New York, NY ; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY. 7. Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY ; Institute for Computational Biomedicine, Weill Medical College of Cornell University, New York, NY. 8. Department of Urology, Weill Medical College of Cornell University, New York, NY. 9. Department of Pathology, Kyungpook National University School of Medicine, Daegu, South Korea. 10. Department of Pathology, School of Medicine, Catholic University of Daegu, Daegu, South Korea. 11. School of Health and Medical Sciences, Örebro University, Örebro, Sweden ; Department of Urology, Örebro University Hospital, Örebro, Sweden. 12. Departments of Clinical Epidemiology and Biostatistics, School of Health and Medical Sciences, Örebro University, Örebro, Sweden. 13. Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY ; Centre for Integrative Biology, University of Trento, Trento, Italy. 14. Department of Pathology and Laboratory Medicine, Institute of Precision Medicine, Weill Medical College of Cornell University, New York, NY ; Department of Urology, Weill Medical College of Cornell University, New York, NY ; Institute for Precision Medicine, Weill Medical College of Cornell University, New York, NY.
Abstract
BACKGROUND: Recurrent mutations in the Speckle-Type POZ Protein (SPOP) gene occur in up to 15% of prostate cancers. However, the frequency and features of cancers with these mutations across different populations is unknown. OBJECTIVE: To investigate SPOP mutations across diverse cohorts and validate a series of assays employing high-resolution melting (HRM) analysis and Sanger sequencing for mutational analysis of formalin-fixed paraffin-embedded material. DESIGN SETTING AND PARTICIPANTS: 720 prostate cancer samples from six international cohorts spanning Caucasian, African American, and Asian patients, including both prostate-specific antigen-screened and unscreened populations, were screened for their SPOP mutation status. Status of SPOP was correlated to molecular features (ERG rearrangement, PTEN deletion, and CHD1 deletion) as well as clinical and pathologic features. RESULTS AND LIMITATIONS: Overall frequency of SPOP mutations was 8.1% (4.6% to 14.4%), SPOP mutation was inversely associated with ERG rearrangement (P<.01), and SPOP mutant (SPOPmut) cancers had higher rates of CHD1 deletions (P<.01). There were no significant differences in biochemical recurrence in SPOPmut cancers. Limitations of this study include missing mutational data due to sample quality and lack of power to identify a difference in clinical outcomes. CONCLUSION: SPOP is mutated in 4.6% to 14.4% of patients with prostate cancer across different ethnic and demographic backgrounds. There was no significant association between SPOP mutations with ethnicity, clinical, or pathologic parameters. Mutual exclusivity of SPOP mutation with ERG rearrangement as well as a high association with CHD1 deletion reinforces SPOP mutation as defining a distinct molecular subclass of prostate cancer.
BACKGROUND: Recurrent mutations in the Speckle-Type POZ Protein (SPOP) gene occur in up to 15% of prostate cancers. However, the frequency and features of cancers with these mutations across different populations is unknown. OBJECTIVE: To investigate SPOP mutations across diverse cohorts and validate a series of assays employing high-resolution melting (HRM) analysis and Sanger sequencing for mutational analysis of formalin-fixed paraffin-embedded material. DESIGN SETTING AND PARTICIPANTS: 720 prostate cancer samples from six international cohorts spanning Caucasian, African American, and Asian patients, including both prostate-specific antigen-screened and unscreened populations, were screened for their SPOP mutation status. Status of SPOP was correlated to molecular features (ERG rearrangement, PTEN deletion, and CHD1 deletion) as well as clinical and pathologic features. RESULTS AND LIMITATIONS: Overall frequency of SPOP mutations was 8.1% (4.6% to 14.4%), SPOP mutation was inversely associated with ERG rearrangement (P<.01), and SPOP mutant (SPOPmut) cancers had higher rates of CHD1 deletions (P<.01). There were no significant differences in biochemical recurrence in SPOPmut cancers. Limitations of this study include missing mutational data due to sample quality and lack of power to identify a difference in clinical outcomes. CONCLUSION:SPOP is mutated in 4.6% to 14.4% of patients with prostate cancer across different ethnic and demographic backgrounds. There was no significant association between SPOP mutations with ethnicity, clinical, or pathologic parameters. Mutual exclusivity of SPOP mutation with ERG rearrangement as well as a high association with CHD1 deletion reinforces SPOP mutation as defining a distinct molecular subclass of prostate cancer.
Authors: Athanasios C Tsiatis; Alexis Norris-Kirby; Roy G Rich; Michael J Hafez; Christopher D Gocke; James R Eshleman; Kathleen M Murphy Journal: J Mol Diagn Date: 2010-04-29 Impact factor: 5.568
Authors: Johan Lindberg; Daniel Klevebring; Wennuan Liu; Mårten Neiman; Jianfeng Xu; Peter Wiklund; Fredrik Wiklund; Ian G Mills; Lars Egevad; Henrik Grönberg Journal: Eur Urol Date: 2012-03-31 Impact factor: 20.096
Authors: Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin Journal: Neoplasia Date: 2010-07 Impact factor: 5.715
Authors: Jesus Gonzalez-Bosquet; Jacob Calcei; Jun S Wei; Montserrat Garcia-Closas; Mark E Sherman; Stephen Hewitt; Joseph Vockley; Jolanta Lissowska; Hannah P Yang; Javed Khan; Stephen Chanock Journal: PLoS One Date: 2011-01-17 Impact factor: 3.240
Authors: Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway Journal: Nature Date: 2011-02-10 Impact factor: 49.962
Authors: Gunther Boysen; Daniel N Rodrigues; Pasquale Rescigno; George Seed; David Dolling; Ruth Riisnaes; Mateus Crespo; Zafeiris Zafeiriou; Semini Sumanasuriya; Diletta Bianchini; Joanne Hunt; Deirdre Moloney; Raquel Perez-Lopez; Nina Tunariu; Susana Miranda; Inês Figueiredo; Ana Ferreira; Rossitza Christova; Veronica Gil; Sara Aziz; Claudia Bertan; Flavia M de Oliveira; Mark Atkin; Matthew Clarke; Jane Goodall; Adam Sharp; Theresa MacDonald; Mark A Rubin; Wei Yuan; Christopher E Barbieri; Suzanne Carreira; Joaquin Mateo; Johann S de Bono Journal: Clin Cancer Res Date: 2018-08-01 Impact factor: 12.531
Authors: Deli Liu; Michael A Augello; Ivana Grbesa; Davide Prandi; Yang Liu; Jonathan E Shoag; R Jeffrey Karnes; Bruce J Trock; Eric A Klein; Robert B Den; Francesca Demichelis; Elai Davicioni; Andrea Sboner; Christopher E Barbieri Journal: J Clin Invest Date: 2021-05-17 Impact factor: 14.808
Authors: Franklin W Huang; Juan Miguel Mosquera; Andrea Garofalo; Coyin Oh; Maria Baco; Ali Amin-Mansour; Bokang Rabasha; Samira Bahl; Stephanie A Mullane; Brian D Robinson; Saud Aldubayan; Francesca Khani; Beerinder Karir; Eejung Kim; Jeremy Chimene-Weiss; Matan Hofree; Alessandro Romanel; Joseph R Osborne; Jong Wook Kim; Gissou Azabdaftari; Anna Woloszynska-Read; Karen Sfanos; Angelo M De Marzo; Francesca Demichelis; Stacey Gabriel; Eliezer M Van Allen; Jill Mesirov; Pablo Tamayo; Mark A Rubin; Isaac J Powell; Levi A Garraway Journal: Cancer Discov Date: 2017-05-17 Impact factor: 39.397